Drug Repurposing: FDA IND Authority Lacks Levers To Better Direct Trial Resources In A Pandemic

 
• By Sarah Karlin-Smith
  
leverage
Global solutions needed to better prioritize trials of repurposed drugs based on likelihood of scientific success, FDA’s Stein said. • Source: Shutterstock

More from Clinical Trials

More from R&D